progressive, locally advanced radioactive iodine-refractory Differentiated Thyroid Cancer (DTC) (DBCOND0147025)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Lenvatinib	A receptor tyrosine kinase inhibitor used for the treatment of metastatic thyroid cancer, advanced renal cell carcinoma in combination with everolimus, and unresectable hepatocellular carcinoma.	Vascular endothelial growth factor receptor 1target Vascular endothelial growth factor receptor 2target Vascular endothelial growth factor receptor 3target Fibroblast growth factor receptor 1target Fibroblast growth factor receptor 2target Fibroblast growth factor receptor 3target Fibroblast growth factor receptor 4target Platelet-derived growth factor receptor alphatarget Proto-oncogene tyrosine-protein kinase receptor Rettarget Mast/stem cell growth factor receptor Kittarget ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Cytochrome P450 3A4enzyme Aldehyde oxidaseenzyme Cytochrome P450 2C8enzyme Cytochrome P450 2C9enzyme Cytochrome P450 1A2enzyme Cytochrome P450 2B6enzyme Cytochrome P450 2C19enzyme Solute carrier family 22 member 6transporter Organic anion transporter 3transporter Solute carrier family 22 member 2transporter Solute carrier organic anion transporter family member 1B1transporter Bile salt export pumptransporter Cytochrome P450 2D6enzyme Solute carrier organic anion transporter family member 1B3transporter

Clinical Trials

Not Available